Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 D...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • Build community with shared future, create better world • National University Receives 2023 Military Friendly® Gold Designation • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • Statement from the Chief Public Health Officer of Canada on World TB Day • Philadelphia Works Names First Female Chief Operating Officer • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

FOSTER CITY, Calif. , February 02 /Businesswire/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.